India, May 18 -- Biotech startup Cellogen Therapeutics has secured Rs.20 Cr (about $2 Mn) in funding from Kotak Alternate Asset Managers (Kotak Alts).

The startup plans to use the capital to advance its CAR‑T clinical programmes, expand its gene therapy pipeline, and strengthen its GMP‑compliant manufacturing and regulatory capabilities.

Kotak Alts made the investment through the Kotak Life Sciences Fund I (KLSF-I), an investment vehicle for early- and growth-stage lifescience and healthtech ventures.

Founded in 2021 by Dr. Gaurav Kharya and Dr. Tanveer Ahmad, Cellogen Therapeutics is a cellular engineering and gene therapy startup. It develops next‑generation therapies utilising Chimeric Antigen Receptor T (CAR-T) ce...